



an Open Access Journal by MDPI

## Drug Resistance and Tumor Microenvironment in Human Cancers

Guest Editors:

**Dr. Tiago Miguel Amaral  
Carvalho**

CICS-UBI—Health Sciences  
Research Centre, University of  
Beira Interior, Av. Infante D.  
Henrique, 6200-506 Covilhã,  
Portugal

**Prof. Dr. Sílvia Socorro**

CICS-UBI—Health Sciences  
Research Centre, University of  
Beira Interior, Av. Infante D.  
Henrique, 6200-506 Covilhã,  
Portugal

**Dr. Marília Isabel Neto  
Figueira**

CICS-UBI—Health Sciences  
Research Centre, University of  
Beira Interior, Av. Infante D.  
Henrique, 6200-506 Covilhã,  
Portugal

Deadline for manuscript  
submissions:

**31 January 2025**

### Message from the Guest Editors

We are calling for manuscripts to be published in the Special Issue ‘Drug Resistance and Tumor Microenvironment in Human Cancers’ of the Biomedicines journal.

The tumor microenvironment is a critical contributor to triggering the acquisition of drug resistance. This Special Issue aims to collect and publish recent discoveries on the influence of the tumor microenvironment in cancer drug resistance. Manuscripts describing research on the cellular and molecular basis of resistance to cancer therapy are welcome. Topics may include, but are not limited to, the role of cancer-associated fibroblasts, immune cells, epithelial cells, endothelial cells, acidosis, hypoxia, extracellular matrix proteins and other components of the tumor microenvironment in acquiring drug resistance. Articles identifying novel markers, new therapeutic targets and promising molecular and cellular drug resistance mechanisms will be highly preferred. Original contributions and review articles on this topic are welcomed.

We look forward to receiving your valuable contributions.



[mdpi.com/si/213814](https://mdpi.com/si/213814)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI